Description
Amyloïdose
Amyloïdose
- Clinical and Biochemical Characterization of Hereditary ATTR Amyloidosis Caused by a Novel Transthyretin Variant V121A (p.V141A)on 28 mai 2025
Int J Mol Sci. 2025 May 13;26(10):4659. doi: 10.3390/ijms26104659.ABSTRACTOver 150 transthyretin (TTR) mutations have been identified in hereditary transthyretin (ATTRv) amyloidosis, and new TTR […]
- Men and women differ with regard to the prevalence, phenotype, and prognosis of wild-type transthyretin amyloid cardiomyopathyon 28 mai 2025
Amyloid. 2025 May 27:1-12. doi: 10.1080/13506129.2025.2507921. Online ahead of print.ABSTRACTBACKGROUND: We explored sex differences in wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) and […]
- Cognitive manifestations and brain integrity in hereditary transthyretin amyloidosis: a systematic reviewon 28 mai 2025
J Neurol. 2025 May 25;272(6):419. doi: 10.1007/s00415-025-13120-1.ABSTRACTBACKGROUND: Central Nervous System involvement in hereditary transthyretin amyloidosis (ATTRv) is present in liver […]
- Skin and soft tissue manifestations in amyloid light-chain amyloidosison 28 mai 2025
Indian J Cancer. 2025 Jan 1;62(1):173-174. doi: 10.4103/ijc.ijc_1489_21. Epub 2025 May 16.NO ABSTRACTPMID:40377625 | DOI:10.4103/ijc.ijc_1489_21
- Localized Amyloidosis of the Oral Cavity: A Rare Clinical Entityon 28 mai 2025
Clin Case Rep. 2025 May 15;13(5):e70413. doi: 10.1002/ccr3.70413. eCollection 2025 May.ABSTRACTAmyloidosis is a complex disease which rarely affects the oral cavity. While localized and systemic […]
- Light-Chain (AL) Amyloidosis as a Rare Cause of Upper Gastrointestinal Bleeding: A Case Report and Systematic Literature Reviewon 28 mai 2025
Case Rep Oncol. 2025 Mar 29;18(1):539-553. doi: 10.1159/000545586. eCollection 2025 Jan-Dec.ABSTRACTINTRODUCTION: Amyloidosis is a rare disease characterized by the deposition of misfolded proteins […]
- Hereditary leptomeningeal transthyretin amyloidosis with heterozygous TTR mutation: a case report and literature reviewon 28 mai 2025
Orphanet J Rare Dis. 2025 May 5;20(1):213. doi: 10.1186/s13023-025-03736-x.ABSTRACTOBJECTIVE: This study aimed to characterize the clinical and neuroimaging features of hereditary leptomeningeal […]
- The causative role of amyloidosis in the cardiac complications of Alzheimer's disease: a comprehensive systematic reviewon 28 mai 2025
J Physiol. 2025 May 5. doi: 10.1113/JP286599. Online ahead of print.ABSTRACTAlzheimer's disease (AD), the leading cause of dementia, is characterised by cerebral amyloid-beta (Aβ) and tau […]
- Validation of a renal staging system and its association with renal amyloid deposition burden in AL amyloidosison 28 mai 2025
Ren Fail. 2025 Dec;47(1):2499230. doi: 10.1080/0886022X.2025.2499230. Epub 2025 May 19.ABSTRACTOBJECTIVES: This study evaluates the relationship between renal amyloid deposition burden in kidney […]
Atteintes cardiovasculaires
Atteintes cardiovasculaires
- Cardiac Amyloidosis: A Narrative Review of Diagnostic Advances and Emerging Therapieson 28 mai 2025
Biomedicines. 2025 May 19;13(5):1230. doi: 10.3390/biomedicines13051230.ABSTRACTBackground/Objectives: Cardiac amyloidosis (CA) is an underdiagnosed and potentially life-threatening infiltrative […]
- How to demonstrate the clinical implication of prophylactic implantable cardioverter-defibrillator in patients with advanced light chain amyloidosison 28 mai 2025
J Arrhythm. 2025 May 26;41(3):e70099. doi: 10.1002/joa3.70099. eCollection 2025 Jun.NO ABSTRACTPMID:40421168 | PMC:PMC12104819 | DOI:10.1002/joa3.70099
- Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert Consensuson 28 mai 2025
JACC Adv. 2025 May 14;4(6 Pt 1):101784. doi: 10.1016/j.jacadv.2025.101784. Online ahead of print.ABSTRACTAmyloidosis, which is caused by misfolded proteins that form amyloid fibrils, is predominantly […]
- Characteristics and outcomes of Black patients with wild type transthyretin cardiac amyloidosison 28 mai 2025
Cardiovasc Revasc Med. 2025 May 7:S1553-8389(25)00234-9. doi: 10.1016/j.carrev.2025.05.006. Online ahead of print.ABSTRACTBACKGROUND: The clinical characteristics and outcomes of Black patients with […]
- Myocardium From Patients With ATTR Amyloidosis Produces Less Force Secondary to Increased Fibrosison 28 mai 2025
JACC Basic Transl Sci. 2025 Apr 7:S2452-302X(25)00124-X. doi: 10.1016/j.jacbts.2025.03.003. Online ahead of print.ABSTRACTAmyloid transthyretin cardiac amyloidosis is one of the most common […]
- The Evolving Therapeutic Paradigm for Cardiac Amyloidosison 28 mai 2025
J Am Coll Cardiol. 2025 May 27;85(20):1907-1910. doi: 10.1016/j.jacc.2025.04.016.NO ABSTRACTPMID:40398970 | DOI:10.1016/j.jacc.2025.04.016
- The American College of Cardology/American Heart Association Heart Failure Staging System Highlights Diagnostic Delay and Predicts Outcome in Transthyretin Cardiac Amyloidosison 28 mai 2025
Mayo Clin Proc. 2025 May 23:S0025-6196(24)00652-9. doi: 10.1016/j.mayocp.2024.11.025. Online ahead of print.ABSTRACTOBJECTIVE: To apply the American College of Cardiology (ACC) and American Heart […]
- Prognostic impact of cardiac resynchronization therapy in wild-type transthyretin amyloid cardiomyopathyon 28 mai 2025
Amyloid. 2025 May 25:1-3. doi: 10.1080/13506129.2025.2504443. Online ahead of print.NO ABSTRACTPMID:40415407 | DOI:10.1080/13506129.2025.2504443
Diagnostic et évaluation
Diagnostic et évaluation
- Multimodality Imaging Leading the Way to a Prompt Diagnosis and Management of Transthyretin Amyloidosison 28 mai 2025
J Clin Med. 2025 May 19;14(10):3547. doi: 10.3390/jcm14103547.ABSTRACTBackground/Objectives: A 43-year-old male presented with neurological symptoms and asymptomatic cardiac dysfunction, left […]
- Exploring the Histopathological Features of Thrombus-Associated Localized Amyloid Deposition: Comprehensive Analysis Employing Immunohistochemistry and Proteomicson 28 mai 2025
Int J Mol Sci. 2025 May 8;26(10):4505. doi: 10.3390/ijms26104505.ABSTRACTAmyloid deposition has been reported to localize within thrombi; however, its pathological characteristics, particularly its […]
- Diagnosis and Management of Mixed Phenotype Hereditary Transthyretin Amyloidosis: A Case-Based, Canadian Perspectiveon 28 mai 2025
CJC Open. 2025 Mar 10;7(5):614-627. doi: 10.1016/j.cjco.2025.03.002. eCollection 2025 May.ABSTRACTHereditary amyloid transthyretin variant (ATTRv) amyloidosis is a rare, life-threatening disease, […]
- Head-to-head comparison of ([18F])florbetapir and ([18F])FDG PET for the early detection of amyloidosis in systemic amyloidosis and plasma cell dyscrasiason 28 mai 2025
Eur J Radiol. 2025 May 21;189:112188. doi: 10.1016/j.ejrad.2025.112188. Online ahead of print.ABSTRACTRATIONALE AND OBJECTIVES: Systemic amyloidosis is underdiagnosed in light-chain amyloidosis (AL), […]
- Role of a Multidisciplinary Program (Amyloidosis Program of Calgary) on Recognition and Intervention for AL and ATTR Amyloidosison 28 mai 2025
Clin Lymphoma Myeloma Leuk. 2025 Apr 17:S2152-2650(25)00140-5. doi: 10.1016/j.clml.2025.04.009. Online ahead of print.ABSTRACTBACKGROUND: The diagnosis and management of amyloidosis requires strong […]
- Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkerson 28 mai 2025
JAMA Netw Open. 2025 May 1;8(5):e258842. doi: 10.1001/jamanetworkopen.2025.8842.ABSTRACTIMPORTANCE: As amyloid-targeted therapies have become commercially available, the monitoring of cerebral […]
- Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real-world data analysison 28 mai 2025
ESC Heart Fail. 2025 Apr 28. doi: 10.1002/ehf2.15311. Online ahead of print.ABSTRACTAIMS AND BACKGROUND: Cardiac amyloidosis leads to functional cardiac impairment and heart failure. Transthyretin […]
- Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosison 28 mai 2025
Am J Hematol. 2025 May 19. doi: 10.1002/ajh.27716. Online ahead of print.ABSTRACTCystatin C (CysC) has emerged as a novel and potentially more reliable biomarker for the estimation of glomerular […]
- Evaluating the Role of Multimodal Imaging in the Diagnosis of Cardiac Amyloidosis and Hypertrophic Cardiomyopathyon 28 mai 2025
Ann Noninvasive Electrocardiol. 2025 May;30(3):e70086. doi: 10.1111/anec.70086.ABSTRACTOBJECTIVE: The objective of this study is to examine the evolving cardiac characteristics of patients with […]
- Novel three-dimensional ECG algorithm for reliable screening for cardiac amyloidosison 28 mai 2025
ESC Heart Fail. 2025 May 4. doi: 10.1002/ehf2.15318. Online ahead of print.ABSTRACTAIMS: Currently, there is no established screening tool for cardiac amyloidosis, leading to a delay in diagnosis in […]
- The potential utility of arterial spin labeling in predicting brain amyloidosison 28 mai 2025
J Clin Neurosci. 2025 May 5;137:111248. doi: 10.1016/j.jocn.2025.111248. Online ahead of print.ABSTRACTBACKGROUND: Declines in regional cerebral blood flow (rCBF) are common in Alzheimer's disease. […]
Interventions et pronostic
Interventions et pronostic
- Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's Diseaseon 28 mai 2025
CPT Pharmacometrics Syst Pharmacol. 2025 May 9. doi: 10.1002/psp4.70038. Online ahead of print.ABSTRACTTo inform an efficient development of new investigational anti-amyloid beta (anti-Aβ) […]
- Predictive Value of Free Light Chain Burden in Patients with AL Amyloidosis Treated with Bortezomib-Based Regimenson 28 mai 2025
Blood Adv. 2025 Apr 30:bloodadvances.2024015528. doi: 10.1182/bloodadvances.2024015528. Online ahead of print.ABSTRACTA difference between involved and uninvolved free light chain (dFLC) equal or […]
- Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathyon 28 mai 2025
JACC Heart Fail. 2025 May;13(5):685-694. doi: 10.1016/j.jchf.2025.03.017.ABSTRACTTransthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy that results from myocardial […]
- Ventilatory efficiency in cardiac amyloidosis-A systematic review and meta-analysison 28 mai 2025
Physiol Rep. 2025 May;13(9):e70308. doi: 10.14814/phy2.70308.ABSTRACTIn cardiac amyloidosis (CA) cardiopulmonary exercise testing (CPET) is underexplored. This study evaluated exercise limitations in […]
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathyon 28 mai 2025
N Engl J Med. 2025 May 8;392(18):1870. doi: 10.1056/NEJMc2501792.NO ABSTRACTPMID:40334171 | DOI:10.1056/NEJMc2501792
- The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer's Dementia: A Systematic Reviewon 28 mai 2025
Ann Indian Acad Neurol. 2025 May 9. doi: 10.4103/aian.aian_547_24. Online ahead of print.ABSTRACTINTRODUCTION: Much research has been conducted into the role and safety of anti-amyloid monoclonal […]
- Successful treatment of lichen amyloidosis with cryotherapyon 28 mai 2025
Indian J Dermatol Venereol Leprol. 2025 Apr 24:1-3. doi: 10.25259/IJDVL_1778_2024. Online ahead of print.NO ABSTRACTPMID:40357938 | DOI:10.25259/IJDVL_1778_2024
- Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experienceon 28 mai 2025
Cancers (Basel). 2025 Apr 25;17(9):1440. doi: 10.3390/cancers17091440.ABSTRACTBackground: Daratumumab-based regimens represent the gold-standard therapy for newly diagnosed AL amyloidosis patients. […]
- Trend of treatment strategy for amyloid light-chain amyloidosis: a-single center experienceon 28 mai 2025
Clin Exp Nephrol. 2025 May 15. doi: 10.1007/s10157-025-02696-7. Online ahead of print.ABSTRACTBefore 2000, AL amyloidosis was considered an incurable disease. However, in the 2000s, autologous […]
- Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summaryon 28 mai 2025
Future Cardiol. 2025 May 15:1-11. doi: 10.1080/14796678.2025.2493019. Online ahead of print.NO ABSTRACTPMID:40371908 | DOI:10.1080/14796678.2025.2493019
- Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studieson 28 mai 2025
Eur Heart J Cardiovasc Pharmacother. 2025 May 17:pvaf033. doi: 10.1093/ehjcvp/pvaf033. Online ahead of print.ABSTRACTAIMS: The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients […]
- Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibodyon 28 mai 2025
Blood Rev. 2025 May 9:101299. doi: 10.1016/j.blre.2025.101299. Online ahead of print.ABSTRACTLight chain (AL amyloidosis) is a rare disorder characterized by the deposition of misfolded light chains […]
- Effective dupilumab treatment for lichen amyloidosis with GATA3+ cell infiltrationon 28 mai 2025
Eur J Dermatol. 2025 Apr 1;35(2):153-155. doi: 10.1684/ejd.2025.4872.NO ABSTRACTPMID:40417907 | DOI:10.1684/ejd.2025.4872
Expériences des patients et des institutions
Expériences des patients et des institutions
- Reliability and validity of the Transthyretin Amyloidosis - Quality of Life (ATTR-QOL) Questionnaire impact scaleson 28 mai 2025
J Patient Rep Outcomes. 2025 Apr 29;9(1):44. doi: 10.1186/s41687-025-00880-7.ABSTRACTBACKGROUND: The diversity of disease phenotypes associated with transthyretin (ATTR) amyloidosis poses challenges […]
- Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical researchon 28 mai 2025
Blood Rev. 2025 May 20:101303. doi: 10.1016/j.blre.2025.101303. Online ahead of print.ABSTRACTSystemic light chain (AL) amyloidosis often results in multi-organ dysfunction and significant morbidity. […]
- Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy homeon 28 mai 2025
Clin Exp Med. 2025 May 27;25(1):179. doi: 10.1007/s10238-025-01683-2.ABSTRACTAdvanced age at diagnosis, comorbidities and invalidating symptoms can debilitate multiple myeloma (MM) and AL amyloidosis […]
Associations
Associations
Pour obtenir les documents
L’accès au texte intégral des documents est restreint au personnel et aux médecins du CHUM en fonction des abonnements de la bibliothèque. Certains documents sont en accès libre sur le web.
Si vous êtes branchés sur le réseau CHUM :
Cliquer sur les liens fournis pour chaque référence pour vérifier la disponibilité du texte intégral.
Pour les articles provenant de PubMed, cliquer préalablement sur le lien suivant pour afficher la disponibilité du document.
Si vous êtes dans un autre établissement et que vous n’arrivez pas à accéder au texte intégral d’un article à partir du lien donné, vérifier auprès de la bibliothèque de votre institution en donnant la référence complète du document.
Avis de non-responsabilité
Le contenu des veilles informationnelles ou stratégiques (ci-après appelée « Veilles ») est mis à votre disposition à titre informatif pour un usage personnel exclusif. Tout usage commercial du contenu des Veilles est strictement interdit. Tous les éléments, articles, rapports ou toute autre source d’information figurant dans les Veilles, vous sont fournis « tels quels », sans garantie d’aucune sorte. Eu égard aux propos tenus dans les articles et les rapports sélectionnés pour les Veilles, le CHUM n’offre aucune garantie notamment d’exhaustivité, de fiabilité, d’actualité et d’exactitude.Le CHUM ne pourra en aucun cas être tenu responsable envers quiconque de tout dommage quel qu’il soit, même ceux directs, encouru notamment des suites de toute réclamation, action ou poursuite découlant, même directement, de l’utilisation de ces Veilles.
Les Veilles contiennent des liens vers des sites Web créés et mis à jour par des tierces parties. Ces liens sont fournis pour la commodité des utilisateurs seulement. Le CHUM n’endosse et ne garantit, ni explicitement ni implicitement, l’exactitude ou l’intégralité ni du contenu de ces hyperliens ni des opinions qui y sont exprimées. Le CHUM n’assume aucune responsabilité à l’égard de ces sites Web externes.
Le CHUM prend tous les moyens raisonnables afin de respecter les droits de propriété intellectuelle afférents au contenu des Veilles et aux modalités du prêt entre bibliothèques, émises par l’Université de Montréal. Le contenu des Veilles, incluant la manière dont il est présenté, sont notamment protégés par la Loi sur le droit d’auteur (L.R.C. (1985), ch. C-42). Le CHUM ne donne aucune garantie et ne fait aucune déclaration à l’effet que le contenu de ces veilles n’enfreint aucun droit d’une autre personne ou entité. Le téléchargement, la reproduction en un seul exemplaire ou le tirage sur papier des Veilles ne sont autorisés qu’à des fins de sauvegarde et pour un usage privé et non commercial. Tout téléchargement, reproduction, édition, diffusion sur Internet, utilisation à des fins commerciales ou publiques, distribution, publication sur un autre site ou sur quelque autre forme ainsi que toute autre utilisation est strictement interdite, à moins d’être faite dans le respect des règles de propriété intellectuelle applicables. |